What is recent in pancreatic cancer immunotherapy?

Complex role for the immune system in initiation and progression of pancreatic cancer. World J Gastroenterol (2014) 1.00

Gastric cancer and the epoch of immunotherapy approaches. World J Gastroenterol (2015) 0.94

New targeted therapies in pancreatic cancer. World J Gastroenterol (2015) 0.87

Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy. Hum Vaccin Immunother (2014) 0.84

Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis? Surg Today (2015) 0.83

Pancreatic cancer, treatment options, and GI-4000. Hum Vaccin Immunother (2014) 0.82

Pancreatic cancer, treatment options, and GI-4000. Hum Vaccin Immunother (2015) 0.80

Novel REIC/Dkk-3-encoding adenoviral vector as a promising therapeutic agent for pancreatic cancer. Cancer Gene Ther (2016) 0.78

Chemo-immunotherapy mediates durable cure of orthotopic Kras(G12D)/p53(-/-) pancreatic ductal adenocarcinoma. Oncoimmunology (2016) 0.75

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol (1997) 29.02

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2007) 25.52

The dendritic cell system and its role in immunogenicity. Annu Rev Immunol (1991) 23.09

Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell (1988) 10.29

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 7.48

Cancer immunology. N Engl J Med (2008) 5.22

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol (2010) 5.21

Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol (2005) 5.09

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol (2010) 4.69

Mesothelin: a new target for immunotherapy. Clin Cancer Res (2004) 4.30

Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res (2001) 4.19

Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene (2009) 3.90

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol (2005) 3.39

Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med (2004) 3.39

Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res (2007) 3.30

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol (2005) 3.28

Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol (2001) 3.27

More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov (2007) 2.68

Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res (2008) 2.67

Immunotherapy: past, present and future. Nat Med (2003) 2.62

Mesothelin targeted cancer immunotherapy. Eur J Cancer (2007) 2.54

Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res (2000) 2.43

Survivin: a new target for anti-cancer therapy. Cancer Treat Rev (2009) 2.37

The Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance. Biochim Biophys Acta (2007) 2.34

Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med (1997) 2.31

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer (2008) 2.31

Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol (2005) 2.21

Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res (2009) 2.17

Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res (1993) 2.15

Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res (2005) 2.05

Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res (1994) 1.90

Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther (2008) 1.90

Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov (2011) 1.89

Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res (2001) 1.82

Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol (1993) 1.80

Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J Clin Oncol (2005) 1.75

Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother (2006) 1.75

Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res (1997) 1.74

Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol (2003) 1.69

Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev (2004) 1.66

Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol (1998) 1.64

Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer (2003) 1.61

Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther (2002) 1.58

Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res (2006) 1.57

MUC1 and MUC2 in pancreatic neoplasia. J Clin Pathol (2004) 1.55

Diagnosis of pancreatic adenocarcinoma by detection of human telomerase reverse transcriptase messenger RNA in pancreatic juice with sample qualification. Clin Cancer Res (2001) 1.55

Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer (2003) 1.51

The epidermal growth factor receptor in human pancreatic cancer. J Pathol (1992) 1.47

Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother (2005) 1.47

Distinct mechanisms of immunosuppression as a consequence of major surgery. Infect Immun (1997) 1.44

RNA interference suppression of MUC1 reduces the growth rate and metastatic phenotype of human pancreatic cancer cells. Clin Cancer Res (2006) 1.40

Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother (2004) 1.36

In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin Cancer Res (2007) 1.35

Telomerase activity is detected in pancreatic cancer but not in benign tumors. Cancer Res (1997) 1.34

MUC1 immunotherapy. Immunotherapy (2010) 1.34

Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer (2000) 1.32

Pancreatoduodenal carcinoma: a clinicopathologic study of 304 patients and immunohistochemical observation for CEA and CA19-9. J Surg Oncol (1991) 1.31

Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. J Clin Invest (2004) 1.30

Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br J Cancer (2006) 1.29

Pancreatic neoplasm in 2011: an update. JOP (2011) 1.28

Immune recognition of self in immunity against cancer. J Clin Invest (2004) 1.27

Current strategies to target p53 in cancer. Biochem Pharmacol (2010) 1.26

Targeted therapies to improve tumor immunotherapy. Clin Cancer Res (2008) 1.25

Carcinoembryonic antigen (CEA) in the diagnosis of pancreatic cancer. Cancer (1973) 1.24

A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther (2008) 1.22

Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer (2001) 1.18

MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugate. Br J Cancer (2004) 1.17

Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet (1995) 1.17

Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur J Immunol (2008) 1.16

A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1. Clin Cancer Res (2004) 1.15

Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. Clin Cancer Res (2005) 1.14

Design and development of synthetic peptide vaccines: past, present and future. Expert Rev Vaccines (2007) 1.14

Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol (2004) 1.13

Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer. Oncol Rep (2009) 1.11

Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer. Clin Cancer Res (2006) 1.09

Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer. Clin Cancer Res (2009) 1.08

Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci (2009) 1.08

Glucocorticoid-induced TNF receptor functions as a costimulatory receptor that promotes survival in early phases of T cell activation. J Immunol (2005) 1.08

GM-CSF gene-modifed cancer cell immunotherapies: of mice and men. Int Rev Immunol (2006) 1.08

Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells. Cancer Res (2002) 1.08

Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol Immunother (2002) 1.08

HER2 overexpression correlates with survival after curative resection of pancreatic cancer. Cancer Sci (2009) 1.08

Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int J Cancer (2011) 1.07

A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. Oncol Rep (2010) 1.07

A novel high-affinity human monoclonal antibody to mesothelin. Int J Cancer (2011) 1.06

A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity. Mol Cancer Ther (2009) 1.05

An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen. Int J Cancer (2009) 1.05

Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes. Anticancer Res (2008) 1.04

Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. Br J Cancer (2006) 1.02

Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft. Cancer Immunol Immunother (2004) 1.02

Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma. Cancer Sci (2004) 1.01

Controversies in the adjuvant treatment of pancreatic adenocarcinoma. JOP (2007) 1.00

Telomerase activity of cultured human pancreatic carcinoma cell lines correlates with their potential for migration and invasion. Cancer (2001) 1.00

Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunol Immunother (2008) 1.00

Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis. Cancer Lett (2003) 0.99

Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts. Ann Oncol (2009) 0.99

Releasable PEGylation of proteins with customized linkers. Adv Drug Deliv Rev (2007) 0.99

Strategies used for MUC1 immunotherapy: human clinical studies. Expert Rev Vaccines (2008) 0.98

Sepsis after major visceral surgery is associated with sustained and interferon-gamma-resistant defects of monocyte cytokine production. Surgery (2000) 0.98

Mice with spontaneous pancreatic cancer naturally develop MUC-1-specific CTLs that eradicate tumors when adoptively transferred. J Immunol (2000) 0.98

Borrelia burgdorferi NapA-driven Th17 cell inflammation in lyme arthritis. Arthritis Rheum (2008) 2.45

HP-NAP inhibits the growth of bladder cancer in mice by activating a cytotoxic Th1 response. Cancer Immunol Immunother (2011) 2.16

Vascular Behçet's disease: new insights in the management of thrombosis. Expert Rev Cardiovasc Ther (2013) 2.00

The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. J Clin Invest (2006) 1.93

Anthrax toxins suppress T lymphocyte activation by disrupting antigen receptor signaling. J Exp Med (2005) 1.90

The Helicobacter pylori vacuolating toxin inhibits T cell activation by two independent mechanisms. J Exp Med (2003) 1.87

IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect (2004) 1.82

Lipoprotein (a) and venous thromboembolism in adults: a meta-analysis. Am J Med (2007) 1.76

Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment. Thromb Haemost (2009) 1.75

Perioperative handling of patients on antiplatelet therapy with need for surgery. Intern Emerg Med (2009) 1.69

Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo. Eur J Immunol (2002) 1.61

Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism. Am J Med (2003) 1.60

Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J Am Coll Cardiol (2009) 1.58

Retinal vein occlusions: a review for the internist. Intern Emerg Med (2010) 1.57

Evaluation of traditional and emerging cardiovascular risk factors in patients with non-arteritic anterior ischemic optic neuropathy: a case-control study. Graefes Arch Clin Exp Ophthalmol (2008) 1.57

Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy. Thromb Haemost (2007) 1.50

Culprit factors for the failure of well-conducted warfarin therapy to prevent ischemic events in patients with atrial fibrillation: the role of homocysteine. Stroke (2005) 1.49

Assessment of platelet function on whole blood by multiple electrode aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy. Am J Clin Pathol (2009) 1.48

Management of oral anticoagulant therapy in the real practice of an anticoagulation clinic: focus on atrial fibrillation. Blood Coagul Fibrinolysis (2005) 1.39

Prophylaxis and treatment of venous thromboembolism in patients with cancer: an update. Intern Emerg Med (2006) 1.39

T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc Natl Acad Sci U S A (2003) 1.37

Frequent loss of heterozygosity without loss of genetic material in acute myeloid leukemia with a normal karyotype. Genes Chromosomes Cancer (2005) 1.28

The neutrophil-activating protein of Helicobacter pylori down-modulates Th2 inflammation in ovalbumin-induced allergic asthma. Cell Microbiol (2008) 1.25

Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment. Am J Hematol (2009) 1.18

Helicobacter pylori secreted peptidyl prolyl cis, trans-isomerase drives Th17 inflammation in gastric adenocarcinoma. Intern Emerg Med (2012) 1.18

Gastric autoimmunity: the role of Helicobacter pylori and molecular mimicry. Trends Mol Med (2004) 1.17

Thrombophilic mutations in high-risk atrial fibrillation patients: high prevalence of prothrombin gene G20210A polymorphism and lack of correlation with thromboembolism. Thromb Haemost (2003) 1.13

The glycopeptide CSF114(Glc) detects serum antibodies in multiple sclerosis. J Neuroimmunol (2005) 1.13

The neutrophil-activating protein of Helicobacter pylori (HP-NAP) as an immune modulating agent. FEMS Immunol Med Microbiol (2007) 1.13

Retracted Multiple sclerosis: the role of cytokines in pathogenesis and in therapies. Int J Mol Sci (2012) 1.11

Risk of bleeding in very old atrial fibrillation patients on warfarin: relationship with ageing and CHADS2 score. Thromb Res (2007) 1.10

Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers. Blood (2010) 1.10

Immunosuppression of TH2 responses in Trichinella spiralis infection by Helicobacter pylori neutrophil-activating protein. J Allergy Clin Immunol (2008) 1.08

Helicobacter pylori, T cells and cytokines: the "dangerous liaisons". FEMS Immunol Med Microbiol (2005) 1.06

Erythrocyte deformability and white blood cell count are associated with aspirin resistance in high-risk vascular patients. Clin Hemorheol Microcirc (2006) 1.05

Human 60-kDa heat shock protein is a target autoantigen of T cells derived from atherosclerotic plaques. J Immunol (2005) 1.05

Perioperative assessment of platelet function by Thromboelastograph Platelet Mapping in cardiovascular patients undergoing non-cardiac surgery. J Thromb Thrombolysis (2013) 1.04

Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study. Blood (2009) 1.02

Nonsteroidal anti-inflammatory drugs suppress T-cell activation by inhibiting p38 MAPK induction. J Biol Chem (2001) 1.02

Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions. Cancer Immunol Immunother (2013) 1.01

Chlamydophila pneumoniae phospholipase D (CpPLD) drives Th17 inflammation in human atherosclerosis. Proc Natl Acad Sci U S A (2012) 0.99

Identification of a posttranslational mechanism for the regulation of hERG1 K+ channel expression and hERG1 current density in tumor cells. Mol Cell Biol (2008) 0.99

Helicobacter pylori, asthma and allergy. FEMS Immunol Med Microbiol (2009) 0.97

Behçet's Disease as a Model of Venous Thrombosis. Open Cardiovasc Med J (2010) 0.95

T-cell response to bacterial agents. J Infect Dev Ctries (2011) 0.95

Helicobacter pylori antigen-specific T-cell responses at gastric level in chronic gastritis, peptic ulcer, gastric cancer and low-grade mucosa-associated lymphoid tissue (MALT) lymphoma. Microbes Infect (2003) 0.95

Tumor-associated macrophages as major source of APRIL in gastric MALT lymphoma. Blood (2011) 0.94

Potential role of M. tuberculosis specific IFN-γ and IL-2 ELISPOT assays in discriminating children with active or latent tuberculosis. PLoS One (2012) 0.94

Orchestration of inflammation and adaptive immunity in Borrelia burgdorferi-induced arthritis by neutrophil-activating protein A. Arthritis Rheum (2013) 0.92

Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: a review of the literature. Semin Thromb Hemost (2011) 0.91

TpF1 from Treponema pallidum activates inflammasome and promotes the development of regulatory T cells. J Immunol (2011) 0.91

Targeting IL-23 in human diseases. Expert Opin Ther Targets (2010) 0.90

Filling the gap between science & clinical practice: prevention of stroke recurrence. Thromb Res (2011) 0.90

Molecular diversity and thrombotic risk in protein S deficiency: the PROSIT study. Hum Mutat (2005) 0.90

Incidence of recurrent venous thromboembolism and of chronic thromboembolic pulmonary hypertension in patients after a first episode of pulmonary embolism. J Thromb Thrombolysis (2010) 0.90

Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events. Am J Cardiol (2006) 0.89

Pulmonary embolism in the elderly: a review on clinical, instrumental and laboratory presentation. Vasc Health Risk Manag (2008) 0.89

The story so far: Helicobacter pylori and gastric autoimmunity. Int Rev Immunol (2005) 0.88

Low vitamin B6 and folic acid levels are associated with retinal vein occlusion independently of homocysteine levels. Atherosclerosis (2007) 0.87

Cardiovascular and thrombophilic risk factors in patients with retinal artery occlusion. Blood Coagul Fibrinolysis (2007) 0.87

Cardiovascular risk assessment beyond Systemic Coronary Risk Estimation: a role for organ damage markers. J Hypertens (2012) 0.87

Behçet's syndrome pathophysiology and potential therapeutic targets. Intern Emerg Med (2014) 0.87

Helicobacter pylori and gastric autoimmunity. Microbes Infect (2004) 0.86

Th17 cells in multiple sclerosis express higher levels of JAK2, which increases their surface expression of IFN-γR2. J Immunol (2012) 0.86

Fibrin resistance to lysis in patients with pulmonary hypertension other than thromboembolic. Am J Respir Crit Care Med (2010) 0.86

High lipoprotein (a) levels are associated with an increased risk of retinal vein occlusion. Atherosclerosis (2009) 0.86

Atherosclerotic and thrombophilic risk factors in patients with ischemic central retinal vein occlusion. Retina (2011) 0.85

The practical management of intracerebral hemorrhage associated with oral anticoagulant therapy. Int J Stroke (2011) 0.85

Hypercoagulability, high tissue factor and low tissue factor pathway inhibitor levels in severe ovarian hyperstimulation syndrome: possible association with clinical outcome. Blood Coagul Fibrinolysis (2003) 0.85

Perioperative handling of antiplatelet drugs. A critical appraisal. Curr Drug Targets (2013) 0.85

Hyperhomocysteinemia and vitamin B6 deficiency: new risk markers for nonvalvular atrial fibrillation? Am Heart J (2004) 0.85

Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy. Hum Vaccin Immunother (2014) 0.84

Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. Haematologica (2006) 0.84

T cells in gastric cancer: friends or foes. Clin Dev Immunol (2012) 0.83

Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention. Thromb Haemost (2009) 0.83

Role of immune response in Yersinia pestis infection. J Infect Dev Ctries (2011) 0.83

New frontiers in cell-based immunotherapy of cancer. Expert Opin Ther Pat (2009) 0.83

Hyperviscosity as a possible risk factor for cerebral ischemic complications in atrial fibrillation patients. Am J Cardiol (2006) 0.83

Defective Vav expression and impaired F-actin reorganization in a subset of patients with common variable immunodeficiency characterized by T-cell defects. Blood (2005) 0.83

Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study. J Thromb Thrombolysis (2009) 0.83

High rate of recurrence in renal transplant recipients after a first episode of venous thromboembolism. Transplantation (2005) 0.83

Nonsteroidal anti-inflammatory drugs inhibit a Fyn-dependent pathway coupled to Rac and stress kinase activation in TCR signaling. Blood (2004) 0.83

The use of cytokines and chemokines in the cancer immunotherapy. Recent Pat Anticancer Drug Discov (2013) 0.83

Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal-transplant recipients. Transplantation (2003) 0.82

Thrombophilic risk factors for symptomatic peripheral arterial disease. J Vasc Surg (2005) 0.82

Helicobacter pylori cag pathogenicity island is associated with reduced expression of interleukin-4 (IL-4) mRNA and modulation of the IL-4delta2 mRNA isoform in human gastric mucosa. Infect Immun (2003) 0.81

Helicobacter pylori: usefulness of an empirical fourth-line rifabutin-based regimen. Expert Rev Gastroenterol Hepatol (2012) 0.81

Role of glycoprotein Ia gene polymorphisms in determining platelet function in myocardial infarction patients undergoing percutaneous coronary intervention on dual antiplatelet treatment. Atherosclerosis (2006) 0.81

Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients. Thromb Haemost (2010) 0.81

Molecular specificity and functional properties of autoreactive T-cell response in human gastric autoimmunity. Int Rev Immunol (2005) 0.81

Reduced erythrocyte deformability and hypercoagulability in idiopathic sudden sensorineural hearing loss. Clin Hemorheol Microcirc (2005) 0.81